Product Description
Mechanisms of Action: NK Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, France, Germany, Greece, Hungary, Italy, Japan, Korea, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Head and Neck Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Bladder Cancer|Breast Cancer|Colorectal Cancer|Muscle Cancer|Small Cell Lung Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PACIFIC-9 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2031-03-25 |
|
| jRCT2021210072 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-10-18 |
|
| D9078C00001 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2030-05-31 |
|
| PACIFIC-9 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-05-29 |